Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing at $56/share

Tarsus Pharmaceuticals, Inc.

Gross proceeds of ~$125M from sale of 2,098,519 shares at $56.00 and pre-funded warrants for 133,625 shares at $55.9999.
PIPE includes participation from Alkeus investors (TCGX, Bain Capital, Wellington) and new investors (ADAR1, Sirenia, RTW, Vestal Point).
Proceeds to fund clinical development, commercial activities, and general corporate purposes; closing expected Aug 7, 2026.
PIPE is in connection with pending acquisition of Alkeus Pharmaceuticals (announced separately).
Barclays lead placement agent; BofA Securities and William Blair co-placement agents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.